skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


HBW Insightでは一般用医薬品(OTC)、ビタミンなどのサプリメント(栄養補助食品)、化粧品の3分野を主にカバーして、世界のコンシューマーヘルスケア産業のニュースをお伝えします。







  • 企業の合併&買収
  • 新製品発表&上市
  • 広告戦略
  • レギュレーションの変更&施行
  • スイッチOTC医薬品
  • 小売業の発展



  • 規制およびコンプライアンス
  • 法規制の動向
  • 安全性の課題



  • 増加傾向にある栄養補助食品
  • 規制上および法律上の落とし穴
  • 競合製品の開発状況
  • マーケティング戦略
  • 広告の取り扱いに関する課題
  • 新成分に関する表示



  • HBW Insight : コンシューマーヘルスケア産業のニュース

    No Plans To Remove CBD Products From Shelves, Says UK Food Regulator

    29 Jan 2020


    CBD products already on the UK market are safe for now, as the country's Food Standards Agency says it will not take action while it works out how to implement the new European Union novel food regulations. 

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

    By Malcolm Spicer 27 Jan 2020


    CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Polish Industry Fighting Against Advertising Tax On Supplements

    By Tom Gallen 27 Jan 2020

    Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    OTC Zantac And Private Label Ranitidine Numerous In FDA Recall Updates

    15 Jan 2020

    In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Bayer Harnessing Skin Microbiome In New Product Development

    By Tom Gallen 15 Jan 2020

    Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions. 

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    EU Wellness Market In 2019: The CBD Green Rush

    By Tom Gallen 09 Jan 2020

    An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Steripod Bolt-on Deal Extends Perrigo Into Toothbrush And Razor Accessories

    By Eileen Francis 08 Jan 2020

    Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    'Supplement' on CBD Product Label A Bullseye For US Litigants, Says Attorney

    18 Dec 2019

    Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Reckitt Targets UK's Painful 'Tweens' With Double-Strength Nurofen

    18 Dec 2019

    Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    US Senate Passes First Monograph Reform Bill After House Passed Three

    11 Dec 2019

    Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Fragrance Creators Association Readies New Consumer Website To Cap 'Year For The Public'

    11 Dec 2019

    Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Future of CBD In Supplements: NDI Notification Looms As Regulatory Path

    06 Dec 2019


    Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    GSK Launches OTC Fluticasone In Japan Following Switch

    By Tom Gallen 06 Dec 2019


    GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Sunscreen Industry Faces Major Challenge In GRASE Push That OTC Monograph Reform Would Solve

    28 Nov 2019

    Industry advocates working to support GRASE determinations for eight UV filters are faced with a dilemma. They would like to share nonpublic studies with the FDA on a confidential basis – at least to get initial temperature readings from the agency as to the studies’ usefulness in addressing data gaps – but under the current OTC monograph framework, no such pathway exists.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Complicated Regulatory Odyssey Steers FDA Toward Rule On CBD In Supplements

    27 Nov 2019

    Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.



Richard Faint

Management, Head of Medtech


Richard Faint

Eileen Francis

Reporter-Journalist, Reporter

Washington DC, USA

Eileen Francis

Eileen specializes in

  • Policy and Regulation
  • Commercial Strategy
  • Dietary Supplements
  • OTC

+20 year(s) experience


Ryan Nelson

Editor, Executive Editor - Health, Beauty and Wellness Insight


Ryan Nelson

Ryan specializes in

  • Policy and Regulation
  • Commercial Strategy
  • Cosmetics
  • Dietary Supplements
  • Market Access

+16 year(s) experience




電話:+81 (0)3 6273 4260